A recent Nature Communications study assesses the impact of different coronavirus disease 2019 (COVID-19) vaccine doses on cardiovascular safety in millions of adults in England. Study: Cohort study of cardiovascular safety of different COVID-19 vaccination doses among 46 million adults in England . Image Credit: pedro7merino / Shutterstock.
com Understanding the safety of COVID-19 vaccines The COVID-19 pandemic was caused by the rapid transmission of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To date, SARS-CoV-2 has infected over 700 million individuals worldwide and caused over seven million deaths. Unprecedented and coordinated efforts between governments and the scientific community led to the development of several vaccines, estimated to have prevented about 14.
4 million deaths worldwide in the first year of the pandemic. By autumn 2023, about 90% of the population in England 12 years of age and older received at least one COVID-19 vaccine dose. Research has shown that a minority of vaccinated individuals experience rare cardiovascular complications from COVID-19 vaccines.
For example, adenovirus-based brands like ChAdOx1 have been associated with vaccine-induced thrombotic thrombocytopenia, whereas messenger ribonucleic acid (mRNA)-based vaccines, including Moderna mRNA1273 and Pfizer-BioNTech BNT-162b2, have been associated with some cases of myocarditis. Therefore, assessing the risk of cardiovascular and thrombotic complications from subsequent .